The Faculty of Medicine, Chulalongkorn University, conducted a study to develop a new generation of Pertussis vaccine (recombinant pertussis vaccine) with a reduced dose from 5 μg down to 2 μg of genetically detoxified recombinant pertussis toxin, to maintain immune efficacy at a more affordable price for vulnerable populations to ensure equal access and coverage for the population.

Forbes Asia recognizes Chulalongkorn Business School alumni among Asia’s 30 Under 30 Social Impact Leaders 2025 for their founding of Mindventure, a social enterprise dedicated to addressing mental health challenges among youth and working-age adults in an era marked by pressure, stress, and social isolation.